Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04123353 · ClinicalTrials.gov registry record
Scan-Rescan Sub-Study of MS PATHS
A clinical trial, sponsored by Biogen.
- Completed
- Registry status
- 30
- Enrollment target
NCT04123353: Completed study, sponsored by Biogen.
NCT04123353 is a clinical trial that has completed, run by Biogen. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04123353 has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
The primary objective of this sub-study is to calculate the reproducibility and other technical performance measures of various magnetic resonance imaging (MRI) image analysis algorithms in order to assess their suitability for detecting changes due to multiple sclerosis (MS) in a real-world setting in participants with MS. The secondary objective of this sub-study is to use the primary endpoint results to calibrate measurements across scanners within each MS PATHS center.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-02-11 |
| Est. Completion | 2017-05-09 |
What the finished NCT04123353 record still lists
NCT04123353 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04123353 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04123353 about?
NCT04123353 is a clinical study titled "Scan-Rescan Sub-Study of MS PATHS". The primary objective of this sub-study is to calculate the reproducibility and other technical performance measures of various magnetic resonance imaging (MRI) image analysis algorithms in order to assess their suitability for detecting changes due to multiple sclerosis (MS) in a real-world setting...
What is the current status of trial NCT04123353?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2017-02-11. Estimated completion is 2017-05-09.
Who is sponsoring clinical trial NCT04123353?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI